AGM/EGMApr 29, 2026, 06:37 AM
UTHR 2026 Annual Meeting Set for June 26; Key Proposals Detailed
AI Summary
United Therapeutics Corporation announced its 2026 Annual Meeting of Shareholders will be held virtually on June 26, 2026, with a record date of April 28, 2026. Shareholders will vote on the election of 12 director nominees, an advisory resolution to approve executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst & Young LLP as the independent auditor. The company reported strong 2025 performance with 11% revenue growth, $1.3 billion net income, and a 38% total shareholder return, alongside significant pipeline progress including positive clinical trial results for ralinepag and nebulized Tyvaso, and the commencement of the UKidney™ human clinical trial.
Key Highlights
- 2026 Annual Meeting of Shareholders scheduled for June 26, 2026, virtually.
- Shareholders to vote on election of 12 director nominees.
- Proposals include advisory vote on executive compensation and approval of 2026 Stock Incentive Plan.
- Ratification of Ernst & Young LLP as independent auditor for 2026.
- 2025 revenue grew 11% vs 2024; total shareholder return was 38%.
- 2025 net income was $1.3B; $1.0B returned to shareholders via accelerated share repurchase.
- Ralinepag ADVANCE OUTCOMES study unblinded in early 2026 with highly significant efficacy.
- Nebulized Tyvaso TETON-2 and TETON-1 studies met primary endpoints for idiopathic pulmonary fibrosis.
- World's first human clinical trial of a xeno-organ product, UKidney™, commenced in 2025.